Phase 2 N=78 Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis
Colitis, Ulcerative
Primary: Number of Participants With Any Adverse Events (AE) or Serious Adverse Events (SAE) — 10; 7; 9; 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=326 A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)
Inflammatory Bowel Diseases · Colitis, Ulcerative · Crohn Disease
Primary: Percentage of Participants With Active CD at Day 1 — 45.3 percentage of participants
Phase 2 N=30 Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants Achieving Endoscopic Improvement — 16.7 percentage of participants
Phase 2 N=234 Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants Achieving Clinical Remission (CR) at Week 52 Using Modified Mayo Score (MMS) — 26.0; 18.3 Percentage of participants — p=0.2524
Phase 2 N=224 Phase II Study of HMPL-004 in Patients With Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants With a Clinical Response at Week 8 — 33; 45; 30 Participants
Phase 3 N=433 Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants Achieving Clinical Remission at Week 12 — 27.0; 7.4 Percentage of participants — p=<0.001
Phase 2 N=105 A Trial of Rosiglitazone for Ulcerative Colitis
Ulcerative Colitis · Inflammatory Bowel Disease
Primary: Number of Participants With Improvement of Signs and Symptoms of UC at 12 Weeks — 23; 12 participants — p=.005
Phase 2 N=66 Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
Ulcerative Colitis · Digestive System Diseases · Colitis, Ulcerative
Primary: Number of Subjects With Treatment-related Adverse Events — 5; 7; 7; 14 Participants
Phase 2 N=211 The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis
Ulcerative Colitis
Primary: Clinical Remission — 5; 2; 9; 4 Participants — p=0.1806
Phase 2 N=357 A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants in Clinical Remission at Week 12 — 2.7; 11.3; 16.7; 15.5 percentage of participants — p=0.0213
Phase 2 N=170 Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12 — 12.1; 31.6; 21.8 Percentage of Participants — p=0.0142
Phase 3 N=190 Canadian Active & Maintenance Modified Pentasa Study
Active Ulcerative Colitis · Remission of Ulcerative Colitis
Primary: Active Phase: Proportion of Active Subjects Achieving Overall Improvement — 64.1; 69.2 percentage of participants
Phase 3 N=265 Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
Proctitis · Proctosigmoiditis
Primary: Percentage of Participants Who Achieved Remission — 38.3; 25.8 percentage of participants — p=0.0324
Phase 3 N=281 Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
Proctitis · Proctosigmoiditis
Primary: Percentage of Participants Who Achieved Remission — 44.0; 22.4 percentage of participants — p=<0.0001
Phase 2 N=124 An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis
Colitis, Ulcerative
Primary: Clinical Improvement Rate (Number of Subjects Showing Clinical Improvement/Number of Subjects Evaluated x 100) — 31.4; 24.1; 44.4; 30.0 percentage of participants
Phase 2 N=32 ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Subjects With Treatment-emergent Adverse Events — 18; 5 Participants — p=0.2096
Phase 3 N=1,447 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Ulcerative Colitis
Primary: Percentage of Participants With Clinical Remission at Week 12 — 13.3; 24.2 percentage of participants — p=0.00006
Phase 3 N=390 Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis
Ulcerative Colitis
Primary: Proportion of Participants With Clinical Remission Per Mayo Score at Week 8 — 9.2; 10.0; 18.5 Proportion of participants — p=0.031
Phase 3 N=268 Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Treatment Success Patients at Week 6, ITT (Intent to Treat) Population — 59.2; 71.8 Percentage of Participants — p=0.0357
Phase 2 N=124 An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis
Colitis, Ulcerative
Primary: Number of Subjects Who Achieve Clinical Remission at Week 8 Using Modified Mayo Score. — 7; 12 Participants — p=0.106
Phase 2 N=41 An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis
Colitis, Ulcerative
Primary: Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Score (MMS) at Week 8 — 17.1 percentage of participants
Phase 3 N=354 Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants Achieving Clinical Remission — 24.8; 15.2 Percentage of participants — p==0.026
Phase 3 N=228 Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)
Ulcerative Colitis
Primary: Proportion of Subjects With Remission — 19; 13 Participants — p=>0.05
N/A N=2,239 European Safety Registry in Ulcerative Colitis (P04808)
Ulcerative Colitis
Primary: Percentage of Participants Within Each of Nine Pre-specified Adverse Event (AE) Categories — 9.1; 3.4; 10.5; 13.0 Percentage of participants
Phase 2 N=123 A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis
Active Ulcerative Colitis
Primary: Percentage of Participants With a Clinical Response — 53; 44 percentage of participants
Phase 3 N=829 Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis
Ulcerative Colitis
Primary: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months — 83.7; 81.5 percent of participants
Phase 3 N=32 Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Patients Who Achieved Clinical Response — 57; 35 percentage of patients — p=0.05
Phase 3 N=281 Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis
Ulcerative Colitis
Primary: To Achieve Clinical Remission in Subjects With Active Ulcerative Colitis (UC). — 42; 29 participants — p=0.069
Phase 2 N=249 A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Induction Period: Percentage of Participants With Clinical Remission at Week 12 — 4.8; 15.9; 22.6; 11.5 percentage of participants
Phase 2 N=178 A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
Ulcerative Colitis
Primary: Percentage of Participants in Cohort 1 Achieving Clinical Remission — 26.5; 1.5 Percentage of participants — p=<.0001